RXII RXi Pharmaceuticals Corporation

0.52
+0.01  (2%)
Previous Close 0.50
Open 0.51
Price To book 2.06
Market Cap 12204129
Shares 23,697,338
Volume 298,407
Short Ratio 14.87
Av. Daily Volume 205,451

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 final readout due 2H 2017.
RXI-109-1402
Connective tissue growth factor (CTGF)
Phase 2 enrollment completed - noted September 6, 2017. Data read outs due before the end of 2017.
Samcyprone - RXI-SCP-1502
Cutaneous warts
Phase 2 completion of enrollment announced June 21, 2017. Data due early 2018.
RXI-109-1501
Retinal scarring
Phase 2 complete.
(RXI-109-1401)
Recurrence of keloids after keloid revision surgery
Phase 2 complete.
(RXI-109-1301)
Anti-scarring

Latest News

  1. Featured Company News - RXi Pharma's Chief Business Officer, Alexey Eliseev, to Leave the Company
  2. RXi Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
  3. RXi Pharmaceuticals to Present at BioPharm America's 10th Annual International Partnering Conference
  4. RXi Pharmaceuticals Announces the Departure of Dr. Alexey Eliseev as Chief Business Officer
  5. BioAxone BioSciences Awarded NINDS SBIR Funding for the Development of Self-Delivering RNAi (sd-rxRNA®) for the Treatment of Spinal Cord Injury
  6. RXi Pharmaceuticals Announces Completion of Enrollment of Phase 2 Clinical Trial with Samcyprone for Cutaneous Warts
  7. RXi Pharmaceuticals Corporation Selected to Present at the 8th Annual Investing for Cures Forum
  8. Edited Transcript of RXII earnings conference call or presentation 10-Aug-17 8:30pm GMT
  9. Investor Network: RXi Pharmaceuticals Corporation to Host Earnings Call
  10. RXi Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
  11. RXi Pharmaceuticals Enters into Common Stock Purchase Agreement for Up to $15.0 Million
  12. RXi Pharmaceuticals Advances Immuno-Oncology Pipeline by Selecting Two sd-rxRNA Compounds for Preclinical Development and Sourcing cGMP Manufacturing
  13. RXi Pharmaceuticals Granted 180-Day Extension by Nasdaq Stock Market to Regain Compliance with Listing Requirements
  14. RXi Pharmaceuticals to Webcast Second Quarter 2017 Financial Results on Thursday, August 10, 2017
  15. Today's Research Reports on Stocks to Watch: RXi Pharmaceuticals Corporation and Exelixis Inc.
  16. RXi Pharmaceuticals Provides Update on Clinical Development Programs in New SNNLive Video Interview with StockNewsNow.com
  17. RXi Pharmaceuticals Announces Completion of Enrollment of Phase 1/2 Clinical Trial with RXI-109 for Retinal Scarring
  18. SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating RXi Pharmaceuticals Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors
  19. RXi Pharmaceuticals Announces the Initiation of its Consumer Testing Program with RXI-231
  20. The Life Sciences Report Examines RXi Pharmaceuticals Expanded Collaboration with Norwegian Cancer Firm and Gears Up for 2017 Milestones

SEC Filings

  1. 8-K - Current report 171088265
  2. 424B3 - Prospectus [Rule 424(b)(3)] 171063681
  3. EFFECT - Notice of Effectiveness 171061976
  4. S-1 - General form for registration of securities under the Securities Act of 1933 171041729
  5. D - Notice of Exempt Offering of Securities 171041702
  6. 8-K - Current report 171019693
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 171019682
  8. 424B3 - Prospectus [Rule 424(b)(3)] 171018543
  9. 8-K - Current report 171016464
  10. EFFECT - Notice of Effectiveness 171016290